Effects of adalimumab therapy on disease activity and interferon-γ-mediated biochemical pathways in patients with rheumatoid arthritis

References

• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001; 27:269–281.
   PubMed Web of Science ®Google Scholar
• Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2005; 11:S39–S44.
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med. 2006; 6:13–19.
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344:907–916.
   PubMed Web of Science ®Google Scholar
• Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun. 2009; 33:222–230.
   PubMed Web of Science ®Google Scholar
• Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992; 35:1160–1169.
   PubMed Web of Science ®Google Scholar
• Barrera P, Boerbooms AM, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PN, van de Putte LB, van der Meer JW. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36:1070–1079.
   PubMed Web of Science ®Google Scholar
• Nassonov EL, Samsonov MY, Chichasova NV, Nikiphorova EL, Tilz GP, Demel U, Widner B, Fuchs D. Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford). 2000; 39:808–810.
   PubMed Web of Science ®Google Scholar
• Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol. 1995; 22:406–412.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Snow KM, Bombardier C, Chang CH, Nelson DL, Rubin LA. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 1988; 31:844–849.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Snow KM, Kurman CC, Nelson DL, Keystone EC. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: Correlations with disease activity. J Rheumatol. 1990; 17:597–602.
   PubMed Web of Science ®Google Scholar
• Hannonen P, Tikanoja S, Hakola M, Mottonen T, Viinikka L, Oka M. Urinary neopterin index as a measure of rheumatoid activity. Scand J Rheumatol. 1986; 15:148–152.
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Kaser S, Ledochowski M, Neurauter G, Mur E, Herold M, . Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol. 2003; 30:1935–1939.
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol. 2006; 25:334–337.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER. Interferon gamma blocks the growth of toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA. 1984; 81:908–912.
   PubMed Web of Science ®Google Scholar
• Burke F, Knowles RG, East N, Balkwill FR. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer. 1995; 60:115–122.
   PubMed Web of Science ®Google Scholar
• Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999; 189:1363–1372.
   PubMed Web of Science ®Google Scholar
• Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol. 2003; 24:242–248.
   PubMed Web of Science ®Google Scholar
• Chavele KM, Shukla D, Keteepe-Arachi T, Fuchs D, Pusey CD, Salama AD. Regulation of MPO-specific T-cell responses during disease remission in ANCA-associated vasculitis: The role of tregs, and tryptophan degradation. Arthritis Rheum. 2010; 62:1539–1548.
   PubMed Web of Science ®Google Scholar
• Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis. 2009; 15:1391–1396.
   Google Scholar
• Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52:3403–3412.
   PubMed Web of Science ®Google Scholar
• Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003; 42:617–621.
   PubMed Web of Science ®Google Scholar
• van der Meer JW, Popa C, Netea MG. Side effects of anticytokine strategies. Neth J Med. 2005; 63 3: 78–80.
   PubMed Web of Science ®Google Scholar
• Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997; 43:2424–2426.
   PubMed Web of Science ®Google Scholar
• Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metabol. 2001; 3:175–187.
   Web of Science ®Google Scholar
• Liang GC, Cordero M, Dyer A, Chang RW. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol. 2005; 32:1662–1665.
   PubMed Web of Science ®Google Scholar
• Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, Nüsslein H, Woody J, Kalden JR, Manger B. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol. 1996; 156:1646–1653.
   PubMed Web of Science ®Google Scholar
• Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler. 1989; 370:1063–1069.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, Brown RR, Proctor RA, Voss SD, Spriggs DR, Trump DL, Borden EC. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer. 1992; 69:562–571.
   PubMed Web of Science ®Google Scholar
• Shirey KA, Jung JY, Maeder GS, Carlin JM. Upregulation of IFN-gamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. J Interferon Cytokine Res. 2006; 26:53–62.
   PubMed Web of Science ®Google Scholar
• Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford). 2003; 42:541–548.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol. 2010; 29:1301–1309.
   PubMed Web of Science ®Google Scholar
• Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG. and the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs JD. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF-κB signalling pathways. Ann Rheum Dis. 2010; 69:1315–1320.
   PubMed Web of Science ®Google Scholar
• Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, vonBubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A. Systemic application of CpG-rich DNA suppresses adaptive T-cell immunity via induction of IDO. Eur J Immunol. 2006; 36:12–20.
   PubMed Web of Science ®Google Scholar
• Szántó S, Koreny T, Mikecz K, Glant TT, Szekanecz Z, Varga J. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther. 2007; 9:R50.
   PubMed Web of Science ®Google Scholar
• Adams O, Besken K, Oberdörfer C, MacKenzie CR, Takikawa O, Däubener W. Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections. J Virol. 2004; 78:2632–2636.
   PubMed Web of Science ®Google Scholar
• Couderc M, Payet S, Henquell C, Dubost JJ, Soubrier M. TNFalpha antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis. Joint Bone Spine. 2010; 77:414–417.
   PubMed Web of Science ®Google Scholar
• Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44:1428–1432.
   PubMed Web of Science ®Google Scholar